Spoken Alpha
PASG
Passage BIO, Inc.
Overview
Passage Bio develops gene therapies for neurodegenerative diseases. The company's lead program, PBFT02, is a one-time gene therapy designed to restore progranulin levels in the brain to treat frontotemporal dementia caused by progranulin deficiency, with expansion into other neurodegenerative conditions including ALS and Alzheimer's disease.
Passage BIO, Inc is a Healthcare company operating in Biotechnology with a $10.7M market cap.
Most recent reported earnings: Q3 FY2026 (Nov 8, 2026).
8 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Management language signature
Disclosures
Investor Relations
Extracted from Unknown source, 2026-10-04.
Transcripts
Recent earnings calls
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
- Q4 FY2022Earnings2023-03-0623 Q&A exchanges
- Q3 FY2022Earnings2022-11-1015 Q&A exchanges
- Q2 FY2022Earnings2022-08-064 Q&A exchanges
- Q1 FY2022Earnings2022-05-1620 Q&A exchanges
- Q4 FY2021Earnings2022-03-0321 Q&A exchanges
- Q3 FY2021Earnings2021-11-068 Q&A exchanges
- Q2 FY2021Earnings2021-08-0815 Q&A exchanges
- Q1 FY2021Earnings2021-05-0914 Q&A exchanges
History
Earnings history
- Q3 FY20262026-11-08EPS— vs $-2.16—Rev— vs ——EODHD
- Q2 FY20262026-08-09EPS$-2.44 vs $-2.20-10.9%Rev$0 vs ——EODHD
- Q1 FY20262026-05-18EPS$-2.36 vs $-3.06+22.9%Rev$0 vs ——EODHD
- Q4 FY20252026-03-02EPS$-4.09 vs $-2.80-46.1%Rev$0 vs ——EODHD
- Q3 FY20252025-11-09EPS$-2.44 vs $-2.97+17.8%Rev$0 vs ——EODHD
- Q2 FY20252025-08-11EPS$-2.96 vs $-4.15+28.7%Rev$0 vs ——EODHD
- Q1 FY20252025-05-12EPS$-5.00 vs $-4.47-11.9%Rev$0 vs ——EODHD
- Q4 FY20242025-03-02EPS$-0.20 vs $-0.200.0%Rev$3.2M vs ——EODHD
- Q3 FY20242024-11-12EPS$-4.71 vs $-4.67-0.9%Rev$0 vs ——EODHD
- Q2 FY20242024-08-07EPS$-5.20 vs $-6.20+16.1%Rev$0 vs ——EODHD
- Q1 FY20242024-05-13EPS$-6.00 vs $-6.90+13.0%Rev$0 vs ——EODHD
- Q4 FY20232024-03-03EPS$-0.30 vs $-0.40+25.0%Rev$5.9M vs ——EODHD
- Q3 FY20232023-11-12EPS$-7.93 vs $-8.80+9.9%Rev$0 vs ——EODHD
- Q2 FY20232023-08-06EPS$-8.80 vs $-9.55+7.8%Rev$0 vs ——EODHD
- Q1 FY20232023-05-10EPS$-12.60 vs $-10.15-24.1%Rev$0 vs ——EODHD
- Q4 FY20222023-03-05EPS$-0.49 vs $-0.52+5.8%Rev$0 vs ——EODHD
- Q3 FY20222022-11-09EPS$-9.80 vs $-15.44+36.5%Rev$0 vs ——EODHD
- Q2 FY20222022-08-03EPS$-14.60 vs $-15.93+8.3%Rev$0 vs ——EODHD
- Q1 FY20222022-05-15EPS$-15.80 vs $-18.38+14.0%Rev$0 vs ——EODHD
- Q4 FY20212022-03-02EPS$-0.95 vs $-0.89-6.7%Rev$0 vs ——EODHD
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q3 FY2026 | 2026-11-08 | — | $-2.16 | — | — | — | — | EODHD |
| Q2 FY2026 | 2026-08-09 | $-2.44 | $-2.20 | -10.9% | $0 | — | — | EODHD |
| Q1 FY2026 | 2026-05-18 | $-2.36 | $-3.06 | +22.9% | $0 | — | — | EODHD |
| Q4 FY2025 | 2026-03-02 | $-4.09 | $-2.80 | -46.1% | $0 | — | — | EODHD |
| Q3 FY2025 | 2025-11-09 | $-2.44 | $-2.97 | +17.8% | $0 | — | — | EODHD |
| Q2 FY2025 | 2025-08-11 | $-2.96 | $-4.15 | +28.7% | $0 | — | — | EODHD |
| Q1 FY2025 | 2025-05-12 | $-5.00 | $-4.47 | -11.9% | $0 | — | — | EODHD |
| Q4 FY2024 | 2025-03-02 | $-0.20 | $-0.20 | 0.0% | $3.2M | — | — | EODHD |
| Q3 FY2024 | 2024-11-12 | $-4.71 | $-4.67 | -0.9% | $0 | — | — | EODHD |
| Q2 FY2024 | 2024-08-07 | $-5.20 | $-6.20 | +16.1% | $0 | — | — | EODHD |
| Q1 FY2024 | 2024-05-13 | $-6.00 | $-6.90 | +13.0% | $0 | — | — | EODHD |
| Q4 FY2023 | 2024-03-03 | $-0.30 | $-0.40 | +25.0% | $5.9M | — | — | EODHD |
| Q3 FY2023 | 2023-11-12 | $-7.93 | $-8.80 | +9.9% | $0 | — | — | EODHD |
| Q2 FY2023 | 2023-08-06 | $-8.80 | $-9.55 | +7.8% | $0 | — | — | EODHD |
| Q1 FY2023 | 2023-05-10 | $-12.60 | $-10.15 | -24.1% | $0 | — | — | EODHD |
| Q4 FY2022 | 2023-03-05 | $-0.49 | $-0.52 | +5.8% | $0 | — | — | EODHD |
| Q3 FY2022 | 2022-11-09 | $-9.80 | $-15.44 | +36.5% | $0 | — | — | EODHD |
| Q2 FY2022 | 2022-08-03 | $-14.60 | $-15.93 | +8.3% | $0 | — | — | EODHD |
| Q1 FY2022 | 2022-05-15 | $-15.80 | $-18.38 | +14.0% | $0 | — | — | EODHD |
| Q4 FY2021 | 2022-03-02 | $-0.95 | $-0.89 | -6.7% | $0 | — | — | EODHD |
Source: EODHD. PASG reported actuals as published; sparse fields render as —.
Top executives
Executives who appear on this company's earnings calls in our corpus, with role and tenure sourced from SEC filings. Click any name for the full role timeline and call appearance history. Per-executive behavioral deviation metrics are available to research subscribers.
Peers
Other companies in Healthcare
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
For developers and AI agents
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for PASG.
$ curl https://api.spokenalpha.com/v1/companies/PASGFAQ
Frequently asked about PASG
Where can I find Passage BIO, Inc.'s (PASG) earnings call transcripts?
Spoken Alpha indexes PASG's earnings call transcripts at https://spokenalpha.com/companies/PASG. Each call links to attributed speakers and parsed analyst Q&A. Passage BIO, Inc.'s own investor relations page is at https://www.passagebio.com/investors-and-news/overview/default.aspx.
When was Passage BIO, Inc.'s most recent earnings call?
Passage BIO, Inc. (PASG) held its most recent earnings call on 2023-03-06, covering fiscal Q4 2022.
What sector is PASG in?
Passage BIO, Inc. (PASG) operates in the Healthcare sector (Biotechnology industry).